What is the latest published BDX stock rating?

Becton Dickinson and Company is shown with Hold in the latest published report, analyzed 2026-10-02. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BDX analysis?

The full latest published report, analyzed 2026-10-02, lives at /stocks/BDX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for BDX?

The latest published report analyzed 2026-10-02 gives BDX a fair value of USD 195 and a potential value of USD 324. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the BDX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-02). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BDX Stock: Fundamentals & Analysis | StockMarketAgent.AI

Anmelden Start free

Becton Dickinson and Company (BDX)

NYSE: BDX · USD

—

StockMarketAgent Research · Analyzed 2026-10-02

Our latest published analysis: BDX rated Hold

Becton Dickinson and Company's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$195 / share

Potential value

$324 / share

Upside to FV

+10.1%

Moat

7.2/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$48.2B
P/E (forward)	13.7x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 13.7x
Market cap: $48.2B

Item	P1	P2	P3	P4	P5	Trend
Period	2022-09-30	2023-09-30	2024-09-30	2025-09-30	2026-09-30	Trend
Revenue	$18.87B	$19.37B	$20.18B	$21.84B	—	+5.0%
Gross profit	$8.48B	$8.17B	$9.13B	$9.92B	—	+5.4%
Operating income	$2.28B	$2.11B	$2.40B	$2.58B	—	+4.2%
Net income	$1.78B	$1.48B	$1.71B	$1.68B	—	-1.9%
EPS (diluted)	$4.62	$3.88	$4.61	$4.58	$9.04	+18.3%
EBITDA	$4.41B	$4.40B	$4.82B	$4.96B	—	+4.0%
R&D	$1.26B	$1.24B	$1.19B	$1.27B	—	+0.2%
SG&A	$4.71B	$4.72B	$4.86B	$5.28B	—	+3.9%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	—	—	—	—	—	—	Verkaufen
ABT	Abbott Laboratories	—	—	—	—	—	—	Reduzieren
ACN	Accenture plc	—	—	—	—	—	—	Halten
ALGN	Align Technology Inc.	—	—	—	—	—	—	Reduzieren
ALNY	Alnylam Pharmaceuticals, Inc.	—	—	—	—	—	—	Starker Kauf
AMGN	Amgen Inc.	—	—	—	—	—	—	Kaufen

Base and Bull scenarios

Base55%

Price target

$194.59

+10.1% from spot

The Base scenario envisions steady hospital procedure replenishment supporting core Medical and Interventional consumable franchises. Operational execution through productivity programs counterbalances selective group purchasing pricing concessions, while international markets compound at moderate single-digit rates. With the shares trading at $176.80 against our Fair value of $194.59, this outcome carries a target of $194.59 at an assigned probability of 55.0%, implying an expected return of 10.1%. Disconfirmation would emerge if core consumable volume growth turns negative or if operating margins slip below targeted levels within the next fiscal year.

Steady procedural replenishment in core hospital medical consumables
Operational productivity initiatives counterbalance hospital pricing pressures
Consistent international revenue expansion across Europe and Asia
Free cash flow prioritized for scheduled debt deleveraging and dividend distributions

Bull20%

Price target

$323.86

+83.2% from spot

The Bull scenario reflects sustained market share capture from competitor supply disruptions, accelerating Medical segment volume growth alongside expanding international adoption. Manufacturing automation and operating leverage widen operating margins toward peer benchmark levels, driving accelerated free cash flow that substantially expedites debt retirement. This upside path yields a target of $323.86 with an assigned probability of 20.0%, representing a return of 83.2% toward Potential value of $323.86. Disconfirmation would occur if competitor capacity quickly restores customer volume share or if hospital capital spending slows within the next two fiscal years.

Accelerated hospital consumable market share capture following competitor outages
Operating margin expansion driven by manufacturing scale efficiencies
Rapid free cash flow generation accelerating balance sheet deleveraging
Re-rating of equity multiple closer to diversified healthcare peer medians

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($194.59). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.7%	2.0%	2.2%	2.5%	2.7%
6.2%	$210	$215	$221	$229	$237
6.7%	$198	$202	$206	$212	$218
7.2%	$188	$191	$195	$199	$203
7.7%	$179	$182	$185	$188	$192
8.2%	$172	$174	$177	$179	$182

Scorecard

Published factor rows and weighted composite

Valuation6.0

Management6.5

Balance Sheet4.0

Profitability5.0

Revenue Growth6.0

Risk Assessment6.0

Competitive Moat7.2

Earnings Quality6.0

Capital Efficiency3.5

Weighted composite

5.6/10

Mixed

Category	Score	Reading
Valuation	6.0
Management	6.5
Balance Sheet	4.0
Profitability	5.0
Revenue Growth	6.0
Risk Assessment	6.0
Competitive Moat	7.2
Earnings Quality	6.0
Capital Efficiency	3.5

Ratingverlauf

Das Rating, das die veröffentlichte Research-Ausgabe des jeweiligen Monats trug. Ein Rating vergleicht den Kurs zum Analysezeitpunkt mit dem Fair Value; es ist kein Nachweis, ob die Einschätzung zutraf.

Jahr	Jan	Feb	Mär	Apr	Mai	Jun	Jul	Aug	Sep	Okt	Nov	Dez
2026

Halten

Becton Dickinson and Company (BDX)

Our latest published analysis: BDX rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · BDX

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on BDX

Frequently asked questions

Ratingverlauf